<DOC>
	<DOCNO>NCT00233545</DOCNO>
	<brief_summary>Cutaneous leishmaniasis typically treated parenteral product pentavalent antimony . Miltefosine oral agent show active mucosal leishmaniasis due L braziliensis Bolivia cutaneous leishmaniasis due L panamensis Colombia . This trial intend evaluate miltefosine cutaneous leishmaniasis due L braziliensis Bolivia . Patients randomly assign miltefosine pentavalent antimony . Standard dose regimen use drug .</brief_summary>
	<brief_title>Miltefosine Treat Cutaneous Leishmaniasis Bolivia</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Presentation : At least 1 lesion must ulcerative . Parasitology : Parasitological confirmation 1 lesion make visualization culture leishmania biopsy aspirate lesion . Previous RX : No specific putatively specific therapy leishmaniasis ( Sb , pentamidine , amphotericin B , imidazole , allopurinol ) Other disease : No concomitant diseases history approximately normal complete blood count ( white blood count , hemoglobin , platelet count ) , value liver transaminase ( SGOT ) kidney function test ( creatinine ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>cutaneous</keyword>
	<keyword>leishmaniasis</keyword>
	<keyword>drug</keyword>
	<keyword>miltefosine</keyword>
</DOC>